Semaglutide in Perimenopause: What to Know

Still cycling, but everything feels like it is changing

You are still getting your period, so you keep thinking this is not supposed to be happening yet. But your cycles have gone unpredictable, closer together one month, skipped the next, heavier, then spotting. In the couple of weeks before a period you are ravenous and the food noise is deafening, and then some weeks it eases. The scale is creeping up, mostly around your middle. You have read plenty about menopause weight gain, and a quiet voice keeps saying, I am not in menopause yet, I am still cycling, so does any of that even apply to me? Is it too early for something like semaglutide in perimenopause?

You are not imagining it, and it is not too early. Perimenopause is a distinct, often multi-year window before your final period, and its defining feature is that hormones fluctuate erratically rather than settling into a smooth decline. That fluctuation is what is driving the changes you are noticing.

One thing to be clear about up front. GLP-1 medications are not approved to treat perimenopause. They are prescribed for weight management in eligible patients. Nothing on this page describes them as a hormone treatment or a fix for perimenopause symptoms. This page explains what perimenopause does to weight and appetite while you are still cycling, where GLP-1 weight management fits, and the two things that matter specifically because you can still conceive: contraception and fertility.

Perimenopause is not menopause: the transition years, still cycling

It helps to be precise about the words, because they get used interchangeably and they are not the same thing. As the Cleveland Clinic explains, perimenopause is the transition leading up to menopause, the years when your ovaries are winding down but have not stopped. Menopause itself is a single point in time: twelve months with no period at all. Everything before that is perimenopause.

That distinction is the whole point of this page. Perimenopause commonly begins in your forties, though it can start in your late thirties, and it often lasts several years. During that window you are still menstruating, even if the timing is all over the place. You are still ovulating at least some cycles. And that means you can still be able to conceive.

This is what separates the transition from the settled state that comes after. The menopause weight gain picture, once estrogen has declined and periods have stopped, is a steadier one: a lower hormonal baseline your body has largely adjusted to. Perimenopause is the messier lead-up, when the hormones are still swinging and your reproductive system is still active. If you want the full picture of what happens after the transition, that companion page covers it. This page stays with the window you are in now, because being still cycling changes what matters, both for how your weight behaves and for two practical considerations most articles skip.

Why estrogen fluctuates, not just declines, and why that changes your weight and appetite

Here is the piece that gets lost when perimenopause is lumped in with menopause. During the transition, estrogen does not fall in a straight line. It swings. Some cycles it spikes higher than it did in your thirties, then crashes low before the next period, then does something different the following month. It is a rollercoaster, not a downhill slope. Those unpredictable swings are exactly why the changes feel so inconsistent: some weeks you feel like yourself, and some weeks you do not.

Those swings show up on the scale and in your appetite even while you are still cycling. Research published in the International Journal of Obesity that followed women through the menopausal transition, not after it, found that visceral fat, the deeper fat around your organs, increased and resting energy expenditure decreased during the transition itself.^[2] In other words, the shift toward midsection weight and a slightly slower metabolism begins in perimenopause, while periods are still happening. Data from the Study of Women’s Health Across the Nation (SWAN), published in JCI Insight, similarly tracked fat gain and loss of lean muscle across the transition rather than only afterward.^[3] The full mechanism of how this settles out is covered on the menopause weight gain page; what matters here is that it starts now.

There is also the appetite side, and this is where you may recognize yourself. The intrusive, hard-to-ignore food thoughts you may know as food noise can track the erratic cycle, spiking in the back half when hormones are crashing and easing when they steady. Add the disrupted sleep that is common in perimenopause, which is itself linked to stronger appetite and cravings, and you get a moving target. Research in the journal Climacteric frames weight gain across the transition as a product of these hormonal and aging changes, not of women suddenly eating more or trying less.^[1] The food noise that comes and goes is not a willpower dip. It is your biology recalibrating in real time.

Where GLP-1 weight management fits during perimenopause, and where it does not

Here is the honest boundary. GLP-1 medications are not a treatment for perimenopause. They do not replace or regulate estrogen, and they are not hormone therapy. Do not expect them to help with hot flashes, mood swings, sleep disruption, or anything about your cycle. What they do is act on appetite and digestion.

GLP-1 medications reduce appetite and slow how quickly your stomach empties, which for many people quiets the constant food noise and makes a smaller, steadier intake feel manageable rather than like a fight. When the hormonal swings of perimenopause have pushed your appetite around and tilted the intake side of the equation against you, that mechanism addresses one specific piece of the picture. It does not touch the hormones themselves. It works on the hunger and food-noise signaling that the hormones have amplified.

That is the accurate way to frame semaglutide in perimenopause, and the limits matter. A GLP-1 is a weight management tool a provider may consider as part of a broader plan, not a fix for the transition and not a standalone answer. Because muscle and bone matter more than ever in this stage, that broader plan includes how you eat while your appetite is smaller. We keep the nutrition tactics on a dedicated page rather than repeating them here; see how to eat on a GLP-1 in perimenopause for the specifics on protein, bone, and steady energy.

Because you are still cycling: birth control and fertility

This is the part the settled-menopause articles cannot address, because it only applies while you are still cycling. Two documented points are worth knowing, and both end the same way: raise them with your provider.

Birth control. If you rely on the pill, this matters. A GLP-1 that slows how quickly your stomach empties may affect how your body absorbs oral contraceptives. That is a documented consideration, not a reason to stop anything on your own or to assume your birth control will fail. The right move is simply to tell your provider what you use so it can be factored into the plan. We walk through the details in our guide on how GLP-1 medications can affect oral birth control. We are not recommending a specific method or dose here; that is a conversation for you and your provider.

Fertility and pregnancy. GLP-1 medications are not used during pregnancy or when trying to conceive. Documented guidance is to stop a GLP-1 approximately two months before trying to conceive. Because you may still be able to conceive in perimenopause, even with irregular cycles, this matters even if another pregnancy is not the plan. If pregnancy is a possibility for you, that belongs in the conversation with your provider. Our guide on GLP-1 medications and fertility covers the guidance in more detail. Again, this is documented guidance to discuss with your provider, not medical advice about your specific situation.

None of this is a reason for alarm. It is the opposite: honest information about the still-cycling reality that the after-the-fact menopause page cannot speak to, so you can raise the right things at the right time.

What the research shows

The large clinical trials behind GLP-1 medications were conducted with FDA-approved branded products, and what they actually tested matters here.

In the STEP 1 trial, published in the New England Journal of Medicine, adults with overweight or obesity who received semaglutide for weight management lost significantly more weight than those on placebo over 68 weeks, alongside lifestyle support.^[4] In the SURMOUNT-1 trial, also in the New England Journal of Medicine, adults with obesity who received tirzepatide for weight management saw substantial reductions in body weight compared with placebo.^[5] Both trials enrolled large numbers of women in the perimenopausal age range, so this population was well represented in the data. Neither trial was designed to study perimenopause specifically, so they tell you how the medications performed in a broad population, not what happens for you based on where you are in the transition.

What the trials do not tell you is exactly what will happen for you. Results vary by individual and depend on many factors, including your starting point, your health history, and the nutrition and activity plan around the medication. Your provider will help you understand what a realistic outcome looks like for your situation.

One critical clarification about what these findings apply to. Every result described above comes from FDA-approved branded products. Transformation Health works with compounded semaglutide and tirzepatide. Compounded medications are not FDA-approved. They have not been independently evaluated by the FDA for safety, efficacy, or quality, and they may differ from branded versions in formulation, purity, or potency. The trial data is evidence about the branded medications tested, not a promise about a compounded product.

How Transformation Health approaches weight management in perimenopause

When you complete an assessment with Transformation Health, your information goes to an independent, licensed provider. That provider reviews your health history, including where you are in the transition, your current medications such as contraception or hormone therapy if you use it, your labs where available, and your goals. If you have started hormone therapy for symptoms, as some perimenopausal women do, that is relevant information for any provider considering a GLP-1.

The provider makes a clinical judgment about whether GLP-1 treatment for weight management is appropriate for your specific situation. Being in perimenopause does not by itself qualify or disqualify you; eligibility is based on BMI and health history, not on menstrual status. You may be a candidate, and a licensed provider makes the final determination. If a GLP-1 is appropriate, your medication is prepared by a licensed US compounding pharmacy, and our coaching emphasizes protein and resistance training so the weight you lose is more likely to be fat rather than the muscle you want to protect through this stage.

The goal is not lifelong medication. It is to use the medication as a runway that quiets food noise and makes new habits possible, then to build the nutrition and strength foundation that lets you eventually reduce or step off it.

Residents of Arkansas, Delaware, Mississippi, New Mexico, Rhode Island, Washington DC, and West Virginia are required by state law to complete a live video consultation before a prescription can be written.

What to know about our medications

Transformation Health works exclusively with US-based, licensed compounding pharmacies. Our semaglutide and tirzepatide are compounded medications, not FDA-approved branded products.

Here is what that means in plain terms. Semaglutide and tirzepatide are the active ingredients in certain FDA-approved branded medications. Compounded versions are prepared by a licensed compounding pharmacy and are not FDA-approved. They have not been independently evaluated by the FDA for safety, efficacy, or quality, and they may differ from branded versions in formulation, purity, or potency. Any clinical trial data on safety or efficacy applies to the branded products, not to compounded versions.

Compounded semaglutide is available as an injectable or an oral option. Compounded tirzepatide is injectable. Our microdose GLP-1 program is also injectable. Your provider will recommend which medication, dose, and delivery method is appropriate for you.

Our pricing is all-inclusive. Your monthly fee covers medication, lab work (through Quest or Labcorp), provider care, and access to our coaching team. No hidden fees. You can cancel anytime.

How to get started

Get a GLP-1 Prescription Complete a free online assessment. Tell us about your weight history, where you are in the perimenopause transition, your current medications including any contraception, and your goals. An independent, licensed provider reviews your information and responds to let you know whether treatment is appropriate for you.

You can also review our GLP-1 Eligibility Guide if you want to understand the full qualification criteria before starting an assessment.

If PCOS or insulin resistance is also part of your history, our guide on GLP-1 and PCOS covers another hormone-driven weight condition GLP-1 medications are used to address, one of several topics in our guide to GLP-1 and specific health conditions. If protecting muscle through this stage is on your mind, our guide on protecting muscle and body composition covers that too.

Citations

[1] Davis SR, Castelo-Branco C, Chedraui P, et al. “Understanding weight gain at menopause.” Climacteric. 2012;15(5):419-429. PMID: 22978257.

[2] Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. “Increased visceral fat and decreased energy expenditure during the menopausal transition.” International Journal of Obesity. 2008;32(6):949-958. PMID: 18332882.

[3] Greendale GA, Sternfeld B, Huang M, et al. “Changes in body composition and weight during the menopause transition.” JCI Insight. 2019;4(5):e124865. PMID: 30843880.

[4] Wilding JPH, Batterham RL, Calanna S, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021;384(11):989-1002. PMID: 33567185.

[5] Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022;387(3):205-216. PMID: 35658024.